Roanna Ruiz
Stock Analyst at Leerink Partners
(0.85)
# 3,934
Out of 5,127 analysts
59
Total ratings
33.33%
Success rate
-13.01%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $2.35 | -14.89% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $8.13 | +10.70% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.49 | +369.80% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $7.51 | +139.68% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.18 | -15.25% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.95 | +236.13% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $10.95 | +146.58% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $6.21 | +109.34% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $7.00 | +100.00% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $490.83 | -32.77% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $63.32 | -8.40% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $36.53 | -31.56% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.44 | +264.58% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.61 | +66.20% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $35.80 | -46.93% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $67.85 | +76.86% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $10.33 | +384.03% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $16.40 | +143.90% | 6 | Oct 19, 2022 |
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $2.35
Upside: -14.89%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $8.13
Upside: +10.70%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.49
Upside: +369.80%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $7.51
Upside: +139.68%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.18
Upside: -15.25%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.95
Upside: +236.13%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.95
Upside: +146.58%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $6.21
Upside: +109.34%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $7.00
Upside: +100.00%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $490.83
Upside: -32.77%
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $63.32
Upside: -8.40%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $36.53
Upside: -31.56%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.44
Upside: +264.58%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.61
Upside: +66.20%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $35.80
Upside: -46.93%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $67.85
Upside: +76.86%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $10.33
Upside: +384.03%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $16.40
Upside: +143.90%